Lesson · 40 min · Free
Bioavailability & First-Pass Effect
Bioavailability & First-Pass Effect Bioavailability & First-Pass Effect Welcome to this lesson on Bioavailability and the First-Pass Effect, critical concepts in understanding drug disposition and efficacy. For a drug to
Bioavailability & First-Pass Effect
Welcome to this lesson on Bioavailability and the First-Pass Effect, critical concepts in understanding drug disposition and efficacy. For a drug to exert its therapeutic effect, it must reach the systemic circulation and subsequently its target site in sufficient concentration. This lesson will delve into the factors influencing the fraction of an administered dose that reaches the systemic circulation unchanged, and the significant impact of presystemic metabolism. Bioavailability (F) is defined as the fraction of an administered dose of unchanged drug that reaches the systemic circulation. It is a crucial pharmacokinetic parameter, as it directly influences the amount of drug available to bind to its pharmacological targets. Bioavailability is expressed as a fraction (0 to 1) or a percentage (0% to 100%). For intravenous (IV) administration, bioavailability is 1 (or 100%) by definition, as the drug is directly introduced into the systemic circulation. For orally administered drugs, bioavailability is often less than 1 due to several factors, including incomplete absorption from the gastrointestinal (GI) tract, chemical degradation within the GI lumen, and metabolism by enzymes in the gut wall or liver before reaching the systemic circulation. This presystemic elimination is collectively known as the First-Pass Effect.
The First-Pass Effect: Presystemic Elimination
The First-Pass Effect, also known as presystemic metabolism, refers to the phenomenon where a significant proportion of an orally administered drug is metabolized in the gastrointestinal wall or liver before reaching the systemic circulation. This process effectively reduces the amount of active drug available to exert its therapeutic effect. The primary organs involved in the first-pass effect are the intestine (enterocytes) and the liver. Drugs absorbed from the GI tract are transported via the portal vein directly to the liver, which is a major site of drug metabolism. The magnitude of the first-pass effect can vary widely among drugs and can significantly impact dosing regimens. For drugs with extensive first-pass metabolism, a much larger oral dose may be required compared to an IV dose to achieve the same therapeutic concentration. In some cases, the first-pass effect is so extensive that oral administration is not a viable route for the drug. Factors contributing to the first-pass effect include: Enzymatic activity in the gut lumen: Enzymes from gut flora or digestive enzymes can degrade drugs. Metabolism by enterocytes: Cells lining the intestinal wall contain various enzymes (e.g., CYP3A4) that can metabolize drugs before they even enter the portal circulation. Hepatic metabolism: The liver is the primary site of drug metabolism. Drugs absorbed from the GI tract pass through the liver via the portal vein, where they can be extensively metabolized by hepatic enzymes (e.g., cytochrome P450 enzymes, glucuronosyltransferases). The extent of first-pass metabolism can be quantified. The fraction of drug escaping metabolism in the gut wall (F g ) and the fraction escaping hepatic metabolism (F h ) contribute to the overall bioavailability. The overall bioavailability (F) can be approximated as the product of these fractions, assuming complete absorption: F = F_g * F_h However, if absorption (F a ) is also incomplete, the equation becomes: F = F_a * F_g * F_h Where: F_a = Fraction absorbed from the GI lumen into enterocytes F_g = Fraction escaping gut wall metabolism F_h = Fraction escaping hepatic first-pass metabolism It's important to note that these fractions are often difficult to determine independently in vivo, and overall bioavailability is typically measured by comparing the area under the curve (AUC) of plasma concentration-time profiles after oral and intravenous administration: F = (AUC_oral * Dose_IV) / (AUC_IV * Dose_oral) This formula assumes linear pharmacokinetics within the dose range studied. If the dose is the same, it simplifies to: F = AUC_oral / AUC_IV
Key Takeaways:
Bioavailability (F) is the fraction of unchanged drug reaching systemic circulation. For IV administration, F = 1 (100%). For other routes, F ≤ 1. The First-Pass Effect is presystemic elimination of a drug, primarily in the gut wall and liver, before it reaches systemic circulation. Extensive first-pass metabolism reduces bioavailability and often necessitates higher oral doses or alternative routes of administration. Factors influencing first-pass metabolism include enzymatic activity in the gut lumen, enterocytes, and the liver. Bioavailability is clinically determined by comparing AUCs after oral and IV administration.
Practice Exercise:
A new drug, 'X', is being developed. An intravenous dose of 100 mg of drug X results in an AUC of 500 mg*h/L. An oral dose of 200 mg of drug X results in an AUC of 400 mg*h/L. Calculate the absolute bioavailability of drug X. Based on your calculation, what implications might this have for the dosing strategy of drug X when administered orally versus intravenously?
Watch the full lesson — free
This topic is part of Pharmacokinetics & Drug Metabolism, a complete AI-narrated video course. Press play once and watch the entire lecture like a movie.
Start the course free →